Variant Bio
Variant Bio is developing life-saving therapies by studying the genes of people with exceptional health-related traits. By identifying communities with unique genetic architectures and outlier phenotypes, Variant Bio has identified novel human genetic evidence that is the basis for programs with breakthrough potential across multiple therapeutic areas. The company's research is powered by its proprietary Inference platform, which integrates across deep phenotyping and multi-omic data using statistical genetics and AI/ML approaches to identify and validate therapeutic targets. In addition, Variant Bio has established strategic partnerships with Novo Nordisk and Boehringer Ingelheim, validating the strength of the platform and enabling the advancement of novel therapeutic programs through world-class development expertise. With ethics at its core, the company launched an unprecedented benefit-sharing program in 2020, in which it has pledged tangible benefits that directly impact the communities it partners with throughout the world.